

Notice of Allowability	Application No.	Applicant(s)	
	10/006,069	REBAR ET AL.	
	Examiner	Art Unit	
	Christopher H Yaen	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 8/9/2004.
2. The allowed claim(s) is/are 24,86-89,99 and 100.
3. The drawings filed on _____ are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.


GARY NICKOL
PRIMARY EXAMINER

Christopher Yaen
 Art Unit 1642

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Joe Liebeschuetz on 2/7/2005.

The application has been amended as follows:

1-23. (Cancelled)

24. (Currently amended) A nucleic acid according to claim [21] 99, wherein the zinc finger protein is a fusion protein comprising a regulatory domain.

25-85. (Cancelled)

86. (Currently amended) A pharmaceutical composition for modulation of angiogenesis comprising

- (a) a nucleic acid according to claim [21] 99 operably linked to a regulatory sequence, wherein the regulatory sequence allows for expression of the nucleic acid in a cell; and
- (b) a pharmaceutically acceptable carrier or diluent.

87. (Currently amended) The pharmaceutical composition according to claim 86, wherein the nucleic acid is contained in an expression vector.

88. (Currently amended) The pharmaceutical composition according to claim 87, wherein the expression vector is a viral expression vector.

Art Unit: 1642

89. (Currently amended) The pharmaceutical composition according to claim 88, wherein the expression vector is selected from the group consisting of a retroviral expression vector, an adenoviral expression vector, and an AAV expression vector.

90-98. (Cancelled)

Claim 99. (Currently amended) A purified nucleic acid encoding a polypeptide,
wherein the polypeptide comprises a zinc finger protein that binds to a target site in a VEGF
gene so as to modulate expression of the VEGF gene, thereby modulating angiogenesis, wherein
The nucleic acid of claim 22- the zinc finger protein comprises first, second and third fingers comprising segments of amino acids specified in SEQ ID NOS: 55, 247 and 68 respectively.

Claim 100. (Currently amended) A vector comprising the nucleic acid of claim [21] 99.

All rejections and or objections are withdrawn in view of the applicant's amendments and arguments thereto as set forth in the paper filed 8/9/2004.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H Yaen whose telephone number is 571-272-0838. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christopher Yaen
Art Unit 1642
February 17, 2005


GARY NICKOL
PRIMARY EXAMINER